PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1780820
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1780820
Global Fluorescence Guided Surgery Systems Market to Reach US$454.9 Million by 2030
The global market for Fluorescence Guided Surgery Systems estimated at US$208.6 Million in the year 2024, is expected to reach US$454.9 Million by 2030, growing at a CAGR of 13.9% over the analysis period 2024-2030. SPY Systems, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$209.7 Million by the end of the analysis period. Growth in the PDE Systems segment is estimated at 13.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$56.8 Million While China is Forecast to Grow at 18.4% CAGR
The Fluorescence Guided Surgery Systems market in the U.S. is estimated at US$56.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$96.3 Million by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.3% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.
Global Fluorescence Guided Surgery Systems Market - Key Trends & Drivers Summarized
Why Is Fluorescence Guided Surgery Becoming a Game-Changer in Oncology and Neurosurgery?
Fluorescence guided surgery (FGS) is revolutionizing surgical precision by enabling real-time visualization of tumors, lymph nodes, and critical tissues using fluorescent dyes. This technique is particularly valuable in oncology, neurosurgery, and minimally invasive procedures, where precise tumor margin detection is essential for complete resection. The growing adoption of personalized cancer treatment and the increasing prevalence of solid tumors are driving demand for FGS systems. Additionally, advancements in near-infrared (NIR) imaging and targeted fluorescence contrast agents are enhancing surgical accuracy, reducing recurrence rates, and improving patient survival. As precision medicine gains traction, fluorescence guided surgery is becoming a standard in complex surgical interventions.
What Technological Advancements Are Improving Fluorescence Guided Surgery Systems?
Breakthroughs in molecular imaging, AI-powered fluorescence mapping, and biocompatible contrast agents are enhancing the efficacy of FGS systems. The development of targeted fluorescent probes that bind selectively to cancerous tissues is improving tumor visibility and reducing damage to healthy structures. AI-driven imaging software is enabling real-time tissue differentiation, guiding surgeons more effectively during procedures. Additionally, hybrid imaging systems combining fluorescence with other imaging modalities, such as MRI and PET scans, are providing multi-layered insights for better surgical decision-making. The integration of robotic-assisted fluorescence guided surgery is further enhancing precision and reducing invasiveness in complex operations.
How Are Regulations and Market Trends Influencing Fluorescence Guided Surgery?
Regulatory agencies such as the FDA and EMA oversee the approval of fluorescence contrast agents and imaging systems, ensuring their safety and effectiveness. The increasing emphasis on intraoperative imaging and precision oncology is driving the adoption of FGS in cancer treatment protocols. Additionally, the demand for minimally invasive procedures is encouraging hospitals to invest in advanced fluorescence-guided laparoscopic and robotic surgery systems. The expansion of AI-assisted surgical planning tools is also influencing market growth, enabling better preoperative mapping of tumors and vascular structures. As surgical technology evolves, fluorescence guided surgery is becoming an indispensable tool for improving patient outcomes.
What’s Driving the Future Growth of the Fluorescence Guided Surgery Systems Market?
The future of FGS is being shaped by AI-enhanced imaging analytics, next-generation fluorescent contrast agents, and the increasing adoption of robotic-assisted surgical platforms. The development of targeted molecular imaging dyes for specific cancers will further improve tumor localization and surgical precision. AI-powered decision support tools will enhance real-time intraoperative guidance, reducing surgical errors and improving resection completeness. Additionally, the expansion of tele-surgical and remote robotic surgery applications will make FGS more accessible in underserved regions. As demand for precision surgery grows, fluorescence guided surgery will continue to redefine modern surgical oncology and neurosurgery.
SCOPE OF STUDY:
The report analyzes the Fluorescence Guided Surgery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (SPY Systems, PDE Systems, VS3 Iridium Systems, Other Types); Surgery (Open Surgery, Laparoscopy / Endoscopy Surgery); Application (Cancer Surgery Application, Cardiovascular Surgery Application, Other Applications)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 37 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.